EGFR oncogenic mutations predict sensitivity to EGFR inhibitors in NSCLC, but less is known about EGFR “variants of unknown significance.” Using preclinical models, 3D structure analyses, and patient response data, Robichaux et al. show in Nature that mutations in structural regions of EGFR predict responses to different EGFR inhibitors.

Original languageEnglish (US)
Pages (from-to)1455-1457
Number of pages3
JournalCancer Cell
Issue number11
StatePublished - Nov 8 2021

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Structure-based classification of EGFR mutations informs inhibitor selection for lung cancer therapy'. Together they form a unique fingerprint.

Cite this